Literature DB >> 23148194

Efficacy and safety of ultra-long-acting insulin degludec.

Ammar Wakil, Stephen L Atkin.   

Abstract

All patients with type 1 diabetes and significant numbers of those with type 2 diabetes are treated with insulin. Nonadherence to insulin regimen can impact glycaemic control. Insulin degludec is a new generation, ultra-long-acting basal insulin that forms soluble multihexamers at the injection site that slowly release insulin degludec monomers into the circulation giving a prolonged duration of action. Insulin degludec may provide a safe and convenient dosing option for patients who require some flexibility in adhering to an insulin regimen according to their lifestyle or circumstances. In this review we focus on the early phases of insulin degludec development.

Entities:  

Keywords:  hypoglycaemia; insulin degludec; type 1 and type 2 diabetes; ultra-long-acting basal insulin

Year:  2012        PMID: 23148194      PMCID: PMC3474648          DOI: 10.1177/2042018812437181

Source DB:  PubMed          Journal:  Ther Adv Endocrinol Metab        ISSN: 2042-0188            Impact factor:   3.565


  8 in total

1.  Psychological insulin resistance in patients with type 2 diabetes: the scope of the problem.

Authors:  William H Polonsky; Lawrence Fisher; Susan Guzman; Leonel Villa-Caballero; Steven V Edelman
Journal:  Diabetes Care       Date:  2005-10       Impact factor: 19.112

2.  How much do forgotten insulin injections matter to hemoglobin a1c in people with diabetes? A simulation study.

Authors:  Jette Randløv; Jens Ulrik Poulsen
Journal:  J Diabetes Sci Technol       Date:  2008-03

3.  Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial.

Authors:  Bernard Zinman; Greg Fulcher; Paturi V Rao; Nihal Thomas; Lars A Endahl; Thue Johansen; Rebecka Lindh; Andrew Lewin; Julio Rosenstock; Michel Pinget; Chantal Mathieu
Journal:  Lancet       Date:  2011-03-12       Impact factor: 79.321

Review 4.  The underuse of insulin therapy in North America.

Authors:  Matthew C Riddle
Journal:  Diabetes Metab Res Rev       Date:  2002 Sep-Oct       Impact factor: 4.876

Review 5.  A critical review of the literature on fear of hypoglycemia in diabetes: Implications for diabetes management and patient education.

Authors:  Diane Wild; Robyn von Maltzahn; Elaine Brohan; Torsten Christensen; Per Clauson; Linda Gonder-Frederick
Journal:  Patient Educ Couns       Date:  2007-06-19

6.  Adherence to insulin and its association with glycaemic control in patients with type 2 diabetes.

Authors:  L A Donnelly; A D Morris; J M M Evans
Journal:  QJM       Date:  2007-05-15

7.  Insulin degludec in type 1 diabetes: a randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine.

Authors:  Kåre I Birkeland; Philip D Home; Ulrich Wendisch; Robert E Ratner; Thue Johansen; Lars A Endahl; Karsten Lyby; Johan H Jendle; Anthony P Roberts; J Hans DeVries; Luigi F Meneghini
Journal:  Diabetes Care       Date:  2011-01-26       Impact factor: 19.112

8.  Correlates of insulin injection omission.

Authors:  Mark Peyrot; Richard R Rubin; Davida F Kruger; Luther B Travis
Journal:  Diabetes Care       Date:  2010-02       Impact factor: 19.112

  8 in total
  3 in total

Review 1.  Pharmacologic treatment options for type 1 diabetes: what's new?

Authors:  Laura M Nally; Jennifer L Sherr; Michelle A Van Name; Anisha D Patel; William V Tamborlane
Journal:  Expert Rev Clin Pharmacol       Date:  2019-05       Impact factor: 5.045

Review 2.  Insulin degludec and insulin degludec/insulin aspart: a review of their use in the management of diabetes mellitus.

Authors:  Gillian M Keating
Journal:  Drugs       Date:  2013-05       Impact factor: 9.546

Review 3.  Long-term safety and efficacy of insulin degludec in the management of type 2 diabetes.

Authors:  Philippe Thuillier; Zarrin Alavi; Véronique Kerlan
Journal:  Diabetes Metab Syndr Obes       Date:  2015-10-01       Impact factor: 3.168

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.